We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

REAL:NASDAQThe RealReal, Inc. Analysis

Data as of 2026-06-03 - not real-time

$9.79

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The RealReal posted Q1 2026 revenue of $722.5 million, up 19% year‑over‑year, and GMV climbed 24%, signaling strong top‑line momentum. Management highlighted higher‑value transactions and improved operating cash flow of $48.7 million. Despite the topline gains, the company recorded a non‑GAAP loss of $0.63 per share and an operating margin of –1.2%, keeping earnings negative. The balance sheet shows $124 million in cash offset by $465 million of debt and a negative book value per share of –$2.98. Technicals are bearish: the stock trades at $9.79, below the 20‑day, 50‑day and 200‑day SMAs (≈$10.0, $10.3 and $11.7) and volume is trending down. The RSI sits at 46, indicating a neutral momentum, while the MACD histogram is marginally positive but the overall trend remains down‑ward. Volatility is elevated at ~77% over the past 30 days and beta is 2.88, implying the stock moves nearly three times the market.
A discounted cash‑flow model values the firm at only $1.77 per share, far below the current price, classifying the equity as overvalued. Analysts, however, have a strong‑buy consensus with a median price target of $17, suggesting a potential upside of roughly 70‑80% if the company can turn profitable. The Extreme Greed sentiment on the fear‑greed index reflects market enthusiasm despite the financial headwinds. The lack of dividend and the negative equity further heighten downside risk. Investors should weigh the growth narrative against the valuation gap and heightened volatility when forming a position.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price below major moving averages
  • high volatility and beta
  • negative earnings despite revenue beat

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • double‑digit revenue growth
  • improving operating cash flow
  • analyst upgrade and upside potential

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • need to achieve sustainable profitability
  • negative book value and high debt
  • valuation gap versus DCF

Key Metrics & Analysis

Financial Health

Revenue Growth18.50%
Profit Margin-9.03%
P/E Ratio43.6
ROA-2.15%
P/B Ratio-3.3
Op. Cash Flow$48.7M
Free Cash Flow$19.6M

Technical Analysis

TrendBearish
RSI46.0
Support$8.69
Resistance$13.39
MA 20$10.00
MA 50$10.31
MA 200$11.74
MACDBullish
VolumeDecreasing
Fear & Greed Index92.73

Valuation

Fair Value$1.77
Target Price$17.25
Upside/Downside76.20%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.88
Volatility76.92%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.